|
PubMed
|
L01.470.750.500.650 |
|
|
Databases, Bibliographic
|
L01.470.750.500 |
|
|
Mitogen-Activated Protein Kinase Kinases
|
D020929 |
[A serine-threonine protein kinase family whose members are components in protein kinase cascades activated by diverse stimuli. These MAPK kinases phosphorylate MITOGEN-ACTIVATED PROTEIN KINASES and are themselves phosphorylated by MAP KINASE KINASE KINASES. JNK kinases (also known as SAPK kinases) are a subfamily.
] |
|
Subdural Effusion
|
C10.228.228.709.675 |
|
|
Dexmedetomidine
|
D020927 |
[A imidazole derivative that is an agonist of ADRENERGIC ALPHA-2 RECEPTORS. It is closely-related to MEDETOMIDINE, which is the racemic form of this compound.
] |
|
Mitogen-Activated Protein Kinases
|
D020928 |
[A superfamily of PROTEIN-SERINE-THREONINE KINASES that are activated by diverse stimuli via protein kinase cascades. They are the final components of the cascades, activated by phosphorylation by MITOGEN-ACTIVATED PROTEIN KINASE KINASES, which in turn are activated by mitogen-activated protein kinase kinase kinases (MAP KINASE KINASE KINASES).
] |
|
Receptors, Interleukin-6
|
D019947 |
[Cell surface receptors that are specific for INTERLEUKIN-6. They are present on T-LYMPHOCYTES, mitogen-activated B-LYMPHOCYTES, and peripheral MONOCYTES. The receptors are heterodimers of the INTERLEUKIN-6 RECEPTOR ALPHA SUBUNIT and the CYTOKINE RECEPTOR GP130.
] |
|
Hypoxia-Ischemia, Brain
|
D020925 |
[A disorder characterized by a reduction of oxygen in the blood combined with reduced blood flow (ISCHEMIA) to the brain from a localized obstruction of a cerebral artery or from systemic hypoperfusion. Prolonged hypoxia-ischemia is associated with ISCHEMIC ATTACK, TRANSIENT; BRAIN INFARCTION; BRAIN EDEMA; COMA; and other conditions.
] |
|
Receptors, Interleukin-4
|
D019948 |
[Receptors present on a wide variety of hematopoietic and non-hematopoietic cell types that are specific for INTERLEUKIN-4. They are involved in signaling a variety of immunological responses related to allergic INFLAMMATION including the differentiation of TH2 CELLS and the regulation of IMMUNOGLOBULIN E production. Two subtypes of receptors exist and are referred to as the TYPE I INTERLEUKIN-4 RECEPTOR and the TYPE II INTERLEUKIN-4 RECEPTOR. Each receptor subtype is defined by its unique subunit composition.
] |
|
Medetomidine
|
D020926 |
[An agonist of RECEPTORS, ADRENERGIC ALPHA-2 that is used in veterinary medicine for its analgesic and sedative properties. It is the racemate of DEXMEDETOMIDINE.
] |
|
Androstenedione
|
D06.472.040.502.112 |
|
|
17-Ketosteroids
|
D06.472.040.502 |
|
|
REM Sleep Parasomnias
|
D020923 |
[Abnormal behavioral or physiologic events that are associated with REM sleep, including REM SLEEP BEHAVIOR DISORDER.
] |
|
Urocortins
|
D06.472.699.857 |
|
|
Anesthesia Department, Hospital
|
N02.278.216.500.968.070 |
|
|
Urological Manifestations
|
D020924 |
[Clinical disturbances of the urinary system.
] |
|
Amino Acid Substitution
|
D019943 |
[The naturally occurring or experimentally induced replacement of one or more AMINO ACIDS in a protein with another. If a functionally equivalent amino acid is substituted, the protein may retain wild-type activity. Substitution may also diminish, enhance, or eliminate protein function. Experimentally induced substitution is often used to study enzyme activities and binding site properties.
] |
|
alpha-Thalassemia
|
C15.378.071.141.150.875.100 |
|
|
Thalassemia
|
C15.378.071.141.150.875 |
|
|
Dexfenfluramine
|
D02.092.471.683.338 |
|
